THOR Synthorx Inc.

17.35
-0.38  -2%
Previous Close 17.73
Open 17.82
Price To Book 3.69
Market Cap 561,060,414
Shares 32,337,776
Volume 79,296
Short Ratio
Av. Daily Volume 91,302
Stock charts supplied by TradingView

NewsSee all news

  1. Synthorx to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ:THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will

  2. Synthorx Reports Third Quarter Financial Results

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ:THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results

  3. Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ:THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1/2 data presented at SITC November 9, 2019.
THOR-707 (HAMMER)
Soild tumors

Latest News

  1. Synthorx to Present at Upcoming Investor Conferences

    SAN DIEGO, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ:THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced the Company will

  2. Synthorx Reports Third Quarter Financial Results

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ:THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today reported financial results

  3. Synthorx to Present THOR-809 Data at the American College of Rheumatology (ACR) Annual Meeting

    SAN DIEGO, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Synthorx, Inc. (NASDAQ:THOR), a clinical-stage biotechnology company developing optimized therapeutics for cancer and autoimmune disorders, today announced that preclinical